Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, CytomX Therapeutics Inc’s stock clocked out at $0.67, up 0.14% from its previous closing price of $0.67. In other words, the price has increased by $0.14 from its previous closing price. On the day, 0.67 million shares were traded. CTMX stock price reached its highest trading level at $0.6668 during the session, while it also had its lowest trading level at $0.623.
Ratios:
To gain a deeper understanding of CTMX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.25 and its Current Ratio is at 1.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on May 28, 2024, Upgraded its rating to Overweight and sets its target price to $3.50 from $2.25 previously.
On May 09, 2024, Wedbush Upgraded its rating to Outperform which previously was Neutral but kept the price unchanged to $8.
Jefferies Upgraded its Hold to Buy on May 06, 2024, whereas the target price for the stock was revised from $2.50 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 18 ’25 when McCarthy Sean A. sold 37,656 shares for $0.60 per share. The transaction valued at 22,556 led to the insider holds 995,195 shares of the business.
Ogden Christopher sold 8,551 shares of CTMX for $5,122 on Mar 18 ’25. The Chief Financial Officer now owns 201,026 shares after completing the transaction at $0.60 per share. On Mar 18 ’25, another insider, Chu Yu-Waye, who serves as the Chief Medical Officer of the company, sold 4,025 shares for $0.60 each. As a result, the insider received 2,411 and left with 135,725 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 53410616 and an Enterprise Value of -37827396. As of this moment, CytomX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 1.70. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39. Its current Enterprise Value per Revenue stands at -0.274 whereas that against EBITDA is -1.413.
Stock Price History:
The Beta on a monthly basis for CTMX is 1.32, which has changed by -0.6883178 over the last 52 weeks, in comparison to a change of 0.086116076 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $5.85, while it has fallen to a 52-week low of $0.56. The 50-Day Moving Average of the stock is -13.21%, while the 200-Day Moving Average is calculated to be -38.96%.
Shares Statistics:
It appears that CTMX traded 1.87M shares on average per day over the past three months and 1755030 shares per day over the past ten days. A total of 80.10M shares are outstanding, with a floating share count of 78.13M. Insiders hold about 2.56% of the company’s shares, while institutions hold 58.41% stake in the company. Shares short for CTMX as of 1740700800 were 4696740 with a Short Ratio of 2.51, compared to 1738281600 on 4552893. Therefore, it implies a Short% of Shares Outstanding of 4696740 and a Short% of Float of 5.8999999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
